HeartFlow reported second-quarter 2026 results, delivering revenue growth alongside expanded margins as the cardiovascular diagnostics company continues scaling its AI-powered coronary artery disease screening platform.
The company's Q2 revenue climbed 28% year-over-year, driven by increased adoption of its FFRCT technology, which uses artificial intelligence and computational fluid dynamics to assess blockages in coronary arteries without invasive catheterization. This non-invasive approach addresses a $4 billion addressable market in coronary artery disease diagnosis.
HeartFlow expanded gross margins to 71%, up from 66% in the prior-year quarter, reflecting operational leverage as the company scales its software-as-a-service model. The company achieved adjusted EBITDA profitability in Q2, a milestone demonstrating the path to sustainable economics. Operating expenses remained disciplined relative to revenue growth, with sales and marketing spending growing at a slower rate than topline results.
Management highlighted strong adoption momentum among cardiologists and interventional radiologists across major U.S. health systems. The company signed new contracts with hospital networks and expanded reimbursement coverage with additional payers, supporting volume growth. Reimbursement coverage now encompasses the majority of insured patients in the United States.
HeartFlow raised full-year 2026 revenue guidance, projecting 25-28% growth, up from prior guidance. The company also expects to maintain adjusted EBITDA profitability throughout the year, signaling confidence in unit economics.
Shares responded positively to the results and forward guidance. The earnings call underscored HeartFlow's transition from a high-growth, cash-burning startup to a profitable, scale-phase medical technology company. With reimbursement tailwinds and payer adoption accelerating, the company appears positioned to capture meaningful share in the coron